Myogen To Present At The JPMorgan Healthcare Conference

DENVER, Jan. 5 /PRNewswire-FirstCall/ -- Myogen, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that J. William Freytag, President and Chief Executive Officer, will present a corporate overview at the 24th Annual JPMorgan Healthcare Conference.

The presentation will take place at 8:00 a.m. (Pacific) on Tuesday, January 10, 2006. There will be a live webcast of the presentation, which will be accessible through a link posted on the investor relations section of the Myogen website at The webcast will be available for replay on Myogen's website through January 31, 2006.

Myogen has two product candidates in late-stage clinical development: ambrisentan for the treatment of patients with pulmonary arterial hypertension (PAH) and darusentan for the treatment of patients with resistant hypertension (RHTN). The Company, in collaboration with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit the company's website at

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties, including those to be discussed in the presentation and others that can be found in the "Risk Factors" section of Myogen's Form 10-K for the year ended December 31, 2004 and Myogen's periodic reports on Form 10-Q and Form 8-K. Myogen does not undertake any obligation to update any forward-looking statements contained in the anticipated presentation as a result of new information, future events or otherwise. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release or the presentation. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.

Myogen, Inc.

CONTACT: Derek K. Cole, Director, Investor Relations of Myogen, Inc.+1-303-464-3986,

Back to news